companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories












Company Directories & Business Directories

PHARMA PLUS DRUGMART

BRACEBRIDGE-Canada

Company Name:
Corporate Name:
PHARMA PLUS DRUGMART
Company Title:  
Company Description:  
Keywords to Search:  
Company Address: 233 Manitoba St,BRACEBRIDGE,ON,Canada 
ZIP Code:
Postal Code:
P1L1S2 
Telephone Number: 7056458044 
Fax Number: 7056453858 
Website:
 
Email:
 
USA SIC Code(Standard Industrial Classification Code):
7384-01 
USA SIC Description:
Photo Finishing-Retail 
Number of Employees:
20 to 49 
Sales Amount:
$2.5 to 5 million 
Credit History:
Credit Report:
Good 
Contact Person:
Leo Krahn 
Remove my name



copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)









Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Your Subject:
Your Comment or Review:
Security Code:



Previous company profile:
PHILLIPS, KENT M MD
PHILLIPS KENT M DR PHYS
PHARMA PLUS DRUGMART
Next company profile:
PHARMA PLUS DRUGMART
PHARMA PLUS DRUGMART
PET VALU










Company News:
  • Pharmaceutical industry | Definition, Overview, History . . .
    The pharmaceutical industry entails the discovery, development, and manufacture of drugs and medications (pharmaceuticals) by public and private organizations
  • Sackler family | Brothers, OxyContin, Purdue Pharma, Opioid Epidemic . . .
    The Sackler family formerly owned the pharmaceutical company Purdue Pharma, known for developing the highly addictive drug OxyContin They gave up control of the company in 2025 as part of a settlement for their involvement in the opioid epidemic
  • Dilip Shanghvi | Biography Facts | Britannica Money
    The son of a wholesale drug distributor, Shanghvi launched Sun Pharma soon after graduating (1982) from the University of Calcutta with a bachelor’s degree in commerce
  • Aventis | Pharmaceuticals, Healthcare, Merger | Britannica Money
    Aventis, former French pharmaceutical company founded in 1999 through the merger of the German firm Hoechst and the French company Rhône-Poulenc With headquarters in Strasbourg, France, Aventis was the product of the first transnational merger to combine large rival companies from France and Germany It became part of the French pharmaceutical conglomerate Sanofi-Aventis in 2004
  • Prescription Drug Costs - Encyclopedia Britannica
    Date of Removal: July 13, 2005 Manufacturer: Purdue Pharma Medical Use: narcotic painkiller Cause for Recall: high levels of Palladone could slow or stop breathing or cause coma or death; combining the drug with alcohol use could lead to rapid release of hydromorphone, in turn leading to potentially fatally high levels of drugs in the system [75]
  • The Opioid Crisis | Britannica
    Sackler family, American family, former owners of the pharmaceutical company Purdue Pharma Although the family is well known
  • McKinsey Company | Consulting Firm, Controversies, Facts - Britannica
    The company also worked with Purdue Pharma, the maker of OxyContin, throughout the opioid crisis Sales of the drug had been declining, so McKinsey wrote proposals with the goal to “turbocharge” its sales, ultimately making about $86 million for consulting for Purdue
  • The Opioid Epidemic | History, Impact on Families, Lawsuits, Fentanyl . . .
    No single settlement was as large as the $7 4 billion agreement Purdue Pharma reached with all 50 states, Washington D C , and four U S territories in June 2025, to be paid out over 15 years to support prevention, treatment, and recovery programs
  • Pharmaceuticals, Vaccines, Facts - Britannica Money
    Like most “big pharma” companies, AstraZeneca’s future depends on its ability to: Maintain a pipeline of new and improved treatments in order to manage its revenue streams as patents for its key drugs expire The company has upped its R D spending in recent years, spending nearly $11 billion in 2023 on its pipeline of over 150 projects




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer